Skip to content
Screener

Incyte INCY Restricted Cash

Restricted Cash at other companies

Geron logo
GeronGERN
$1.89M+1.0%
Protagonist Therapeutics logo
Protagonist TherapeuticsPTGX
$287K-1.0%
Syndax Pharmaceuticals logo
Syndax PharmaceuticalsSNDX
$102K-53.0%
Cogent Biosciences, Inc. logo
Cogent Biosciences, Inc.COGT
$416K
Arcutis Biotherapeutics, Inc. logo
Arcutis Biotherapeutics, Inc.ARQT
$308K0.0%
Tyra Biosciences, Inc. logo
Tyra Biosciences, Inc.TYRA
$884K-11.6%

Other financials

Income statement

See full
Revenue$1.7B+37.7%
Gross profit$1.6B+38.0%
Operating income$697.9M+31.6%
Net income$585.6M+44.6%
EPS (diluted)$2.81+37.7%

Balance sheet

See full
Cash & equivalents$4.0B+104%
Total debt$38.3M-9.8%
Total equity$6.3B+52.1%
Total assets$7.9B+35.2%

Cash flow

See full
Operating cash flow$507.7M+1,035%
CapEx$1.6M-43.5%
Free cash flow$509.3M+1,069%

Valuation

See full
Market cap$24.28B+60.1%
Enterprise value$20.34B+53.5%
P/E15.1×-2.4×
P/S4.2×+0.9×

Profitability

See full
Gross margin92.6%-0.3pp
Operating margin30.6%+4.8pp
Net margin27.7%+8.7pp
FCF margin34%+12.3pp

Returns & leverage

See full
Return on equity30.7%+6.4pp
Debt / equity0.0×
Current ratio4.6×+1.7×

Where this comes from

Reported directly by Incyte in its filing.

Tagged under the XBRL concept us-gaap:RestrictedCashNoncurrent.

The source filing: Incyte’s 10-Q, filed July 28, 2026.

Filed
Jul 28, 2026, 4:02 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0000879169-26-000056
Line itemJune 30,2026December 31,2025*
Inventory112,542101,060
Prepaid expenses and other current assets253,087317,831
Total current assets6,026,5725,023,902
Restricted cash1,8161,852
Long term equity investments104,38747,991
Inventory345,026342,232
Property and equipment, net709,469730,885
Finance lease right-of-use assets, net25,55927,520

Item 1. Financial Statements

FAQ

What is Incyte's restricted cash?
Incyte (INCY) reported restricted cash of $1.82M in Q2 2026.
How has Incyte's restricted cash changed year-over-year?
Incyte's restricted cash decreased by 1.5% year-over-year, from $1.84M to $1.82M.
What is the long-term trend for Incyte's restricted cash?
Over 4 years (2021 to 2025), Incyte's restricted cash has grown at a 1.9% compound annual growth rate (CAGR), from $1.72M to $1.85M.
What does restricted cash mean?
Cash restricted for specific purposes by contractual, regulatory, or legal requirements — not available for general corporate use.

Ask your AI about Incyte's restricted cash.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude